Werewolf Therapeutics Inc. (NASDAQ: HOWL)
$2.85
+0.1550 ( +5.76% ) 277.6K
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Market Data
Open
$2.85
Previous close
$2.69
Volume
277.6K
Market cap
$124.28M
Day range
$2.65 - $2.87
52 week range
$1.57 - $8.19
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | May 24, 2024 |
8-k | 8K-related | 15 | May 03, 2024 |
10-q | Quarterly Reports | 63 | May 03, 2024 |
ars | Annual reports | 1 | Apr 12, 2024 |
def | Proxies and info statements | 5 | Apr 12, 2024 |
8-k | 8K-related | 16 | Mar 07, 2024 |
10-k | Annual reports | 91 | Mar 07, 2024 |
8-k | 8K-related | 17 | Feb 09, 2024 |
8-k | 8K-related | 45 | Jan 08, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |